Spotlight On... France's ANSM orders French biotech Theravectys to suspend manufacturing; Potential buyer for Ranbaxy plant in Ireland drops out; India's Alkem says FDA signs off on a plant; and more...

Another French biotech has had its clinical supply manufacturing shut down by French drug regulator ANSM after inspectors found a number of serious problems. According to a recent report posted by the European Medicines Agency, ANSM inspectors in November took a look at Theravectys in Villejuif, France, a biotech which is producing lentiviral vectors for clinical development and doing cell work for chimeric antigen receptors (CARs) and T-cell receptor (TCR)-based cell therapies. The facility was only approved in April of last year. During the inspection, they found 45 deficiencies, 5 of which they deemed critical and 17 major. They included testing media fill with "unqualified equipment." Last year, regulators recommended the same action against TxCell, a French biotech working on T-cell treatments for chronic inflammatory and autoimmune diseases. TxCell has since transferred its manufacturing to a contractor. Access the EMA report here | More

> A potential buyer for a former Ranbaxy plant in Cashel, Ireland, that Sun Pharmaceutical is trying to sell has reportedly dropped out, but others remain interested. Report

> Nepali companies have warned they may shut down unless the government releases the executives that were arrested because their companies allegedly sold products at prices that exceeded price caps. Story

> Indian drugmaker Alkem Laboratories reported Monday to the Bombay Stock Exchange that the FDA has issued am Establishment Inspection Report for an active pharmaceutical ingredient plant in Gujarat following a September 2015 inspection. Filing

> A new report says that Indian companies continue to be the source for a large number of diverted narcotic and psychotropic drugs that end up for sale on illegal online pharmacies. Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.